Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2023 - 2025)
Apimeds Pharmaceuticals US (APUS) reported Other Non-Current Liabilities of $1.6 million for Q4 2025, up 827.06% quarter-over-quarter from $174413.0 in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US has reported Other Non-Current Liabilities for 2 years, with the latest figure at $1.6 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (changed N/A YoY), and the FY2025 full-year result was $1.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $1.6 million, up from $174413.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.6 million in Q4 2025, with the low at $68878.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Apimeds Pharmaceuticals US | 13.93 Mn | 10.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.62 Mn |
| Jun 30, 2025 | 174,413.00 |
| Dec 31, 2023 | 68,878.00 |